Cover - USD ($) $ in Millions |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2022 |
Feb. 17, 2023 |
Jun. 30, 2022 |
|
| Document Information Line Items | |||
| Entity Registrant Name | DERMATA THERAPEUTICS, INC. | ||
| Entity Central Index Key | 0001853816 | ||
| Document Type | 10-K/A | ||
| Amendment Flag | true | ||
| Entity Voluntary Filers | No | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity Well Known Seasoned Issuer | No | ||
| Entity Small Business | true | ||
| Entity Shell Company | false | ||
| Entity Emerging Growth Company | true | ||
| Entity Current Reporting Status | Yes | ||
| Document Period End Date | Dec. 31, 2022 | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Document Fiscal Period Focus | FY | ||
| Document Fiscal Year Focus | 2022 | ||
| Entity Ex Transition Period | true | ||
| Entity Common Stock Shares Outstanding | 12,321,848 | ||
| Entity Public Float | $ 4.0 | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Entity File Number | 001-40739 | ||
| Entity Incorporation State Country Code | DE | ||
| Entity Tax Identification Number | 86-3218736 | ||
| Entity Address Address Line 1 | 3525 Del Mar Heights Rd | ||
| Entity Address Address Line 2 | 322 | ||
| Entity Address City Or Town | San Diego | ||
| Entity Address State Or Province | CA | ||
| Entity Address Postal Zip Code | 92130 | ||
| City Area Code | 858 | ||
| Icfr Auditor Attestation Flag | false | ||
| Auditor Name | Mayer Hoffman McCann, P.C. | ||
| Auditor Location | California | ||
| Auditor Firm Id | 199 | ||
| Local Phone Number | 800-2543 | ||
| Security 12b Title | Common Stock, par value $0.0001 per share | ||
| Trading Symbol | DRMA | ||
| Security Exchange Name | NASDAQ | ||
| Entity Interactive Data Current | Yes | ||
| Amendment Description | Dermata Therapeutics, Inc. (the “Company,” “Dermata,” “we,” “us,” or “our”) hereby amends its Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on February 21, 2023 (the “Form 10-K”), as set forth in this Amendment No. 1 on Form 10-K/A (this “Amendment”). This Amendment is being filed solely to amend and replace Part II, Item 9A. “Controls and Procedures” of the Form 10-K, to reflect the conclusion of the Company’s Principal Executive Officer and Principal Financial Officer that the Company’s internal controls over financial reporting were effective as of December 31, 2022. Except as described above and for currently-dated certifications of the Company’s principal executive officer and principal financial officer filed herewith as Exhibits 31.1 and 31.2, no other changes are being made to the Form 10-K and this Amendment does not modify, amend, or update in any way any of the financial or other information contained in the Form 10-K. Because no | ||
| Common Warrants | |||
| Document Information Line Items | |||
| Security 12b Title | Common Stock Purchase Warrants | ||
| Trading Symbol | DRMAW | ||
| Security Exchange Name | NASDAQ |